Pulmonary manifestations in tuberous sclerosis complex

Am J Med Genet C Semin Med Genet. 2018 Sep;178(3):326-337. doi: 10.1002/ajmg.c.31638. Epub 2018 Jul 28.

Abstract

Tuberous sclerosis complex has manifestations in many organ systems, including brain, heart, kidney, skin, and lung. The primary manifestations in the lung are lymphangioleiomyomatosis (LAM) and multifocal micronodular pneumocyte hyperplasia (MMPH). LAM affects almost exclusively women, and causes cystic lung destruction, pneumothorax, and chylous pleural effusions. LAM can lead to dyspnea, oxygen dependence, and respiratory failure, with more rapid disease progression during the premenopausal years. In contrast, MMPH affects men and women equally, causing small nodular pulmonary deposits of type II pneumocytes that rarely progress to symptomatic disease. Here, we review the clinical features and pathogenesis of LAM and MMPH.

Keywords: TSC; VEGF-D; lymphangioleiomyomatosis; mTOR; sirolimus.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Female
  • Humans
  • Lung / pathology*
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / etiology*
  • Lung Neoplasms / pathology
  • Lymphangioleiomyomatosis / diagnosis
  • Lymphangioleiomyomatosis / drug therapy
  • Lymphangioleiomyomatosis / etiology*
  • Lymphangioleiomyomatosis / pathology
  • Mice
  • Multiple Pulmonary Nodules / genetics
  • Multiple Pulmonary Nodules / pathology*
  • Pneumothorax / etiology
  • Prognosis
  • Sirolimus / therapeutic use
  • Tuberous Sclerosis / etiology*
  • Tuberous Sclerosis / pathology
  • Tuberous Sclerosis Complex 2 Protein / genetics

Substances

  • TSC2 protein, human
  • Tuberous Sclerosis Complex 2 Protein
  • Sirolimus